Device Trial Radar · NCT03118037
Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry
Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
182
Actual
Start
Jun 14, 2017
Primary completion
Nov 11, 2024
Study completion Nov 11, 2024
Sponsor
- Lead sponsor
- GynesonicsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 18, 2017
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SAGE is an observational post market registry with the objective of characterizing long term outcomes after treatment of uterine fibroids with the Sonata System in real world clinical practice settings.
Conditions
- Uterine Fibroid
Interventions
Sonata SystemDevice
Transcervical access for radiofrequency ablation of uterine fibroids
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Pregnancy and Pregnancy OutcomesTime frame: Up to 5 years-post procedure
- Surgical Re-intervention for Heavy Menstrual BleedingTime frame: Up to 5 years-post procedure
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Evangelisches Krankenhaus Köln-Weyertal gemeinnützige GmbH
Cologne, Germany
Frauenklinik Universitätsklinikum Jena
Jena, Germany
Klinik für Frauenheilkunde und Geburtshilfe
Kempten, Germany
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.